A seven-color panel including CD34 and TdT could be applied in > 97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype

T cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% and 25% of newly diagnosed ALL cases in children and adults, respectively [1,2]. In contrast to B cell acute lymphoblastic leukemia (B-ALL), T-ALL is associated with a higher frequency of relapse and less favourable outcomes. Minimal residual disease (MRD) may persist after treatment and eventually lead to clinical relapse.

Source: Leukemia Research - July 15, 2018 Category: Hematology Authors: Ya-Zhe Wang, Le Hao, Yan Chang, Qian Jiang, Hao Jiang, Le-Ping Zhang, Ling-Ling He, Xiao-Ying Yuan, Ya-Zhen Qin, Xiao-Jun Huang, Yan-Rong Liu Source Type: research